Highest-materiality recent filing
Board approved discontinuation of internal discovery programs and closure of Birmingham, AL facility by end 2026.
BioCryst shareholders approve 7M share increase to Stock Incentive Plan
Incentive Plan approved with 119.8M for, 63.3M against, adding 7M shares to the Plan.
ORLADEYO net revenue $148.3M, +11% reported, +21% ex-Europe; GAAP operating loss $701.6M includes $697.8M non-cash IPR&D charge from Astria acquisition.
BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones
BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.
Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.
Merger with Astria Therapeutics completed on January 23, 2026; Astria becomes wholly owned subsidiary.
BioCryst closes $700M Astria acquisition, adds Phase 3 HAE asset navenibart
Acquired Astria for ~$700M net of cash; financed with $396.6M Blackstone loan and 37.3M shares.
BioCryst beats FY2025 ORLADEYO rev guidance; FY2026 outlook $625-645M; Astria acquisition on track
Preliminary unaudited FY2025 ORLADEYO net revenue $601M (+37% YoY), exceeding $590-600M guidance range.
BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack
Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.
BioCryst gets FDA approval for ORLADEYO oral pellets for HAE patients aged 2 to <12 years
FDA approved ORLADEYO oral pellet formulation for prophylactic therapy in HAE children aged 2 to <12 years.
BioCryst board chair Nancy Hutson to retire; Vincent Milano named successor
Nancy J. Hutson notified retirement from BioCryst board, effective earlier of Astria acquisition close or 2026 annual meeting.
BioCryst clears HSR hurdle for Astria acquisition; expects close Q1 2026
HSR waiting period terminated early on December 3, 2025, satisfying one closing condition.
BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria
ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).
BioCryst to acquire Astria Therapeutics for 0.59 shares + $8.55 cash per share; Q3 ORLADEYO strong
Merger: each Astria share → 0.59 BCRX shares + $8.55 cash; expected close Q1 2026.
BioCryst completes sale of European ORLADEYO business; receives $250M upfront
Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.
BioCryst's Chief R&D Officer resigns after CEO selection process; to depart Sep 1, 2025
Dr. Helen Thackray resigns as Chief R&D Officer effective Sep 1, 2025, after not being selected as next CEO.
BioCryst Q2 ORLADEYO rev $156.8M (+45% YoY); net income $5.1M vs loss $12.7M
Q2 total revenue $163.4M (+50% YoY); ORLADEYO net rev $156.8M (+45% YoY).
BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor
Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.
BioCryst appoints Babar Ghias as CFO and Head of Corporate Development
Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.
BioCryst agrees to sell European ORLADEYO business to Neopharmed Gentili for $250M
Upfront cash consideration of $250M plus up to $14M in revenue milestones if achieved before Dec 31, 2032.
BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M
Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.
FDA extends PDUFA goal date for BioCryst's ORLADEYO pediatric NDA to Dec 12, 2025
FDA determined submission of additional final reports and formulation data is a major amendment, extending review by three months.
BioCryst shareholders approve 11M share increase in stock incentive plan at annual meeting
Director George Abercrombie retired effective June 12, 2025 after 13 years; no disagreement cited.
BioCryst extends former CFO Anthony Doyle's consulting agreement through Dec 31, 2025
Consulting Agreement extended from original end date to December 31, 2025; after that, month-to-month with 30-day notice.
FDA accepts NDA for ORLADEYO granules in HAE ages 2-11; priority review, PDUFA Sep 12, 2025
FDA accepted NDA for once-daily ORLADEYO oral granules for HAE patients aged 2-11; priority review granted with PDUFA target Sep 12, 2025.
Q1 ORLADEYO net rev $134.2M (+51% YoY); total rev $145.5M (+56.8% YoY); net income $32K vs loss $35.4M.
BioCryst appoints Steve Frank to board; board size increased to 11
Steven Frank elected to board effective May 2, 2025, filling new seat after board expansion from 10 to 11 directors.
BioCryst CFO Anthony Doyle resigns; CEO Stonehouse takes interim CFO role
CFO Anthony Doyle resigns effective April 9, 2025; will provide transition consulting at $450/hour until May 31.
BioCryst files patent infringement lawsuit against Annora Pharma over generic ORLADEYO
Annora Pharma sought FDA approval for generic ORLADEYO, challenging three patents expiring in 2039.
BioCryst CFO Anthony Doyle to resign effective April 9, 2025; search underway
Anthony Doyle notified resignation as CFO effective April 9, 2025.
BioCryst Q4 ORLADEYO rev $124.2M (+36.6%); FY2025 guidance raised; faces generic challenge
Q4 ORLADEYO net revenue $124.2M (+36.6% YoY); full year 2024 net revenue $437.7M (+34.3% YoY).
BioCryst to present at J.P. Morgan Healthcare Conference on Jan 14; slides posted Jan 13
Presentation at 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Jan 14 at 6:00 p.m. ET.
BioCryst reports FY2024 ORLADEYO net revenue $437M (+34% YoY), guides FY2025 $515-535M
Preliminary FY2024 ORLADEYO net revenue $437M (+34% YoY); Q4 net revenue $123.5M (+36% YoY).
BioCryst raises ORLADEYO WAC 5% to $44,484.33 per 28-day pack effective Jan 8
ORLADEYO WAC raised from $42,366.03 to $44,484.33 per 28-day pack (150mg or 110mg).
BioCryst Q3: ORLADEYO revenue $116.3M (+35.7%); raises FY total revenue guide to $443-448M
Q3 total revenue $117.1M (+35.1% yoy) led by ORLADEYO net revenue of $116.3M.
BioCryst begins Phase 1 trial of BCX17725 (KLK5 inhibitor) for Netherton syndrome
First participant enrolled in Phase 1 trial of BCX17725, a KLK5 inhibitor for Netherton syndrome.
BioCryst awarded up to $69M HHS contract for RAPIVAB supply to Strategic National Stockpile
Contract covers up to 95,625 doses of RAPIVAB over five years for influenza treatment.
BioCryst Q2 ORLADEYO revenue up 34% to $108.3M; raises FY guidance to $420-435M
Q2 total revenue $109.3M (+32.5% YoY); GAAP operating profit $8.8M vs loss $20.7M in Q2 2023.
BioCryst shareholders approve 7M-share increase to Stock Incentive Plan
Stockholders approved amendment increasing authorized shares by 7,000,000 to 70,090,000 total under the plan.
BioCryst Q1 ORLADEYO revenue $88.9M (+30% YoY); 2024 guidance raised to $390-$400M
Q1 net loss narrowed to $35.4M ($0.17/sh) from $53.3M ($0.28/sh) a year ago.
BioCryst FY2023 ORLADEYO rev $326M (+30% yoy); guides $380-400M 2024, expects operating profit
ORLADEYO net revenue $90.9M Q4, $326M FY2023; U.S. patients on paid/free product 1,104 (+30% yoy).
BioCryst adopts amended By-Laws for DGCL compliance and universal proxy card rules
Updates to align with DGCL Sections 219 and 222 regarding stockholder list and meeting adjournment.
Preliminary Q4 ORLADEYO net revenue $89.9M (+27% YoY); full-year 2023 $325M (+29% YoY).
BioCryst director Kenneth B. Lee, Jr. to retire from Board on Dec 31, 2023
Lee notified company Nov 28, 2023 of retirement effective Dec 31, 2023.
BioCryst updates ORLADEYO Japan commercialization; new royalty tier at 80% above threshold
BioCryst Japan K.K. now handles all commercial promotion for ORLADEYO in Japan; Torii to conduct HAE disease awareness.
BioCryst and Clearside partner to develop avoralstat for DME via SCS Microinjector; $5M upfront
License agreement for avoralstat for diabetic macular edema using Clearside's SCS Microinjector.
BioCryst pipeline update: five programs to enter clinic by 2025, R&D spend guided $230-240M in 2024
BCX17725 (fusion protein KLK5 inhibitor) for Netherton syndrome entering clinic 2H 2024.
BioCryst Q3 2023: ORLADEYO revenue $85.7M (+29.8% yoy); net loss narrows to $36.1M
Total Q3 2023 revenue $86.7M (+14.4% yoy), driven by ORLADEYO growth of $19.7M.
BioCryst enrolls first patient in proof-of-concept trial for oral Factor D inhibitor BCX10013
First patient enrolled in open-label, multicenter dose-escalation trial of BCX10013 in up to 15 PNH patients.
BioCryst Q2 ORLADEYO rev $81M (+24% YoY); on track for FY $320M; GAAP EPS ($0.40)
ORLADEYO net revenue $81.0M in Q2 2023, up 24.2% YoY from $65.2M; total revenues $82.5M (+25.9% YoY).
On June 11, 2025, George B. Abercrombie notified BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of his intention to retire from the Board of Directors of the Company (the “Board”), effective as of the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
On April 30, 2025, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven directors and elected Steven Frank to fill the vacancy created by the enlargement of the Board, effective May 2, 2025 (the “Effective Date”).
Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025
appointed Jon P. Stonehouse, the Company’s Chief Executive Officer, to serve as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of the Effective Date.
On February 28, 2025, Anthony Doyle, the Chief Financial Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025.
On November 28, 2023, Kenneth B. Lee, Jr. notified BioCryst Pharmaceuticals, Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”), effective December 31, 2023.
On July 10, 2023, the Board of Directors of the Company appointed Anthony Doyle, the Company’s Chief Financial Officer, to serve as interim Principal Accounting Officer, effective as of the same date.
On July 7, 2023, Michael L. Jones, Executive Director, Finance and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), informed the Company of his intention to resign from the Company.
Also effective September 15, 2022, Dr. Ryan Arnold will serve as the Company’s new Chief Medical Officer.
Effective September 15, 2022, William P. Sheridan, MBBS, will serve as Chief Development Officer of the Company.
On February 4, 2022, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) voted to increase the size of the Board from 11 directors to 12 directors and elected Machelle Sanders to fill the vacancy created by the enlargement of the Board, effective February 8, 2022 (the “Effective Date”).
elected Amy McKee, M.D. to fill the vacancy created by the enlargement of the Board, effective September 20, 2021
Max materiality 0.85 · Median 0.70 · Most common event earnings